1910 (@1910_ai) header
1910 (@1910_ai) profile picture

We are the only AI-native biotech building a Multimodal AI Platform for Modality Agnostic Drug Discovery™

Boston, MA
Joined September 2020
Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)Photo by 1910 (@1910_ai)
▶️ Learn more about our ITO™ Platform, which integrates massive multimodal data, frontier AI models, and high-throughput lab automation to identify novel disease targets and design therapeutics better and faster than traditional approaches.
1
2
4
420
Read our featured publication in J. Med. Chem., “PEGASUS: Unlocking Polarity in Cell-Permeable Cyclic Peptides Using AI Models Built on Massively Parallel Biological Assays”: pubs.acs.org/doi/10.1021/acs…
1
2
78
Learn more about 1910’s flagship AI models: PEGASUS™ Featured Publication in J. Med. Chem.: lnkd.in/etbvf5VH CANDID-CNS™ Publication in JCIM: lnkd.in/gWn2fYiP Read the media exclusive in GEN Edge: lnkd.in/eyr_qb9f
1
1
113
CANDID-CNS™ is our state-of-the-art AI model that offers a breakthrough approach to predicting blood-brain barrier penetration, particularly for bRo5 molecules. Read the full publication in JCIM: pubs.acs.org/doi/10.1021/acs… To Partner on CANDID-CNS™: [email protected]
1
94
CANDID-CNS™ is our state-of-the-art AI model that offers a breakthrough approach to predicting blood-brain barrier penetration, particularly for bRo5 molecules. Published in JCIM: pubs.acs.org/doi/10.1021/acs…
1
1
141
Our founder @JenAsherPhD was featured in a spotlight on 5 women shaping AI x Bio — highlighting Jen's work at 1910, where we're building an AI-native biotech transforming drug discovery with our ITO™ Platform. Read the article: techlifesci.com/p/five-women…
1
1
246
Meet Our Team: Jesse W. Collins, Ph.D., Senior AI Research Scientist. From MIT physics to Harvard Biomechanics to NIH neuroscience, Jesse's interdisciplinary training now powers our CANDID-CNS™ AI model for BBB penetration.
1
99
1910 Unlocks Macrocyclic Peptide Drugs Using PEGASUS AI Model PEGASUS generates permeable macrocyclic peptides, offering new promise for a modality that can combine the properties of a biologic in a pill @jenasherphd @1910_ai #AI #drugdiscovery #peptides hubs.li/Q03ZRTp70
2
1
4
809
Today, @1910_ai is thrilled to announce the publication of PEGASUS™, a state-of-the-art AI model for de novo design and optimization of macrocyclic peptides. ▪️Paper: pubs.acs.org/doi/10.1021/acs… ▪️Press Release: businesswire.com/news/home/2… ▪️ BD: To partner on PEGASUS™, [email protected]
2
2
206
We're excited to announce the publication of PEGASUS™—our breakthrough AI model that solves one of the toughest challenges in drug discovery: designing macrocyclic peptides with oral bioavailability. Featured Article in the Journal of Medicinal Chemistry. 🧵
1
1
2
124
The Journal of Medicinal Chemistry selected PEGASUS™ as a Featured Article for its exceptional novelty and scientific merit. Even AI-skeptical practitioners are calling it a breakthrough in peptide design.
1
2
37
Celebrating 10 well-deserved promotions at 1910 as our team continues advancing the mission to Make Every Pharma Company an AI Company™. Congratulations, Liping, Jesse, Ify, Leerang, Reyal, Cole, Lakshmi, Francis, Mostafa and Sidharth.
1
47